The functional effects of CRF are mediated via the activation of two receptor subtypes, CRF 1 and CRF 2 , that are 70% homologous in their amino acid sequences but appear pharmacologically and anatomically distinct. Both receptor subtypes are members of the G protein-coupled receptor superfamily positively coupled to adenylate cyclase. CRF 1 is the predominant receptor within the pituitary, cerebellum, and neocortex. Two CRF 2 isoforms exist: the CRF 2␣ , which is expressed in limbic regions, e.g., lateral septum and dorsal raphe nucleus; and the CRF 2␤ , more abundant in the periphery (Chalmers et al., 1995) . Moreover, a CRF binding protein (CRF-BP) binds native rat/human CRF with higher affinity than CRF receptors (Behan et al., 1995) . CRF-BP is expressed in the brain of numerous species, where it might regulate CRF-mediated neurotransmission.
A second CRF receptor endogenous agonist, urocortin, has been described (45% homology with CRF) and binds to CRF 2 receptors with a 10-fold higher affinity than CRF. Urocortin mRNA expression is prominent in the Edinger-Westphal nucleus, which does not contain CRF mRNA and is colocalized with the CRF 2␣ receptor mRNA in the rat lateral septum and dorsal raphe nucleus (Vaughan et al., 1995) . Recently, urocortin II, which possesses only 26% homology with CRF, has been cloned and found to be a selective agonist at CRF 2 receptors (Reyes et al., 2001) .
The hypothesis that CRF plays a role in the pathophysiology of affective disorders has been put forward on the basis of experimental behavioral data, and is consistent with the contribution of CRF system alterations to the etiology of psychiatric disorders exacerbated or precipitated by stress. Thus, high levels of cerebrospinal fluid CRF and an increased number of CRF immunoreactive neurons in the hypothalamic paraventricular nucleus have been measured in patients with depressive disorders (Nemeroff et al., 1984) . After electroconvulsive therapy or antidepressant treatment, HPA axis and CRF function normalize, suggesting that CRF overactivity may be a marker for human depression . Moreover, intra-amygdala injection of antisense oligonucleotides directed against the CRF 1 and CRF 2 receptor mRNA in the rat and knock out of the CRF 1 receptor gene in mice have been associated with reduced levels of anxiety and lower anxiogenic responses to i.v. CRF injections (Liebsch et al., 1995; Heinrichs et al., 1997; Smagin and Dunn, 2000) . Furthermore, CRF 1 receptor antagonists have demonstrated anxiogenic effects in rodents (Gutman et al., 2000) .
A number of synthetic CRF 1 receptor antagonists have been identified (Gutman et al., 2000) , e.g., butylethyl-[2,5dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine 526) , 5-chloro-N-cyclopropylmethyl-2-methyl-N-propyl-NЈ-(2,4,6-trichlorophenyl)-pyrimidin-4,6diamine (NBI 27914), 4-(3-pentylamino)-2,7-dimethyl-8-(2methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]pyrimidine (DMP904), 2-[(N-(2-methylthio-4-isopropylphenyl)-Nethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl)-6-methylpyrimidine (CRA 1000), and R-121919 (formerly NBI 30775). However, it is of interest to note that these molecules have close structural similarities, including pyrrolo-, pyrazolo-, and other substituted pyrimidine moieties. The more recent compounds offer better solubility and central nervous system penetration than their predecessors. For example, R-121919 (K i value of 3 nM for the human CRF 1 receptor) has been shown to possess pharmacological activity in experimental models of anxiety after oral administration in the 3-to 30-mg/kg range (Gutman et al., 2000) . Beneficial effects of this compound have been observed in an open clinical trial performed in depressed patients, supporting the view that CRF 1 receptor antagonism could be of therapeutic value in the treatment of depression. However R-121919's development has been stopped because of hepatic toxicity (Zobel et al., 2000) . In the present study, we report on the characterization of a new CRF 1 receptor antagonist, 4-(2chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), obtained by the optimization of a lead compound discovered by random screening of several thousand chemicals. This compound belongs to the novel 2-aminothiazole chemical family ( Fig. 1 ).
Experimental Procedures Animals
Male Sprague-Dawley CD rats and female OF1 mice purchased from Iffa Credo (L'Arbresele, France), and male Mongolian gerbils from Janvier (Le Genest St. Isle, France) were housed in a controlled temperature and light-dark environment with water and chow available ad libitum before the experiments. All experimental procedures were approved by the Animal Care and Use Committee of Sanofi-Synthelabo Recherche and were carried out in accordance with French legislation. Materials SSR125543A ( Fig. 1 ) and antalarmin were synthesized by Sanofi-Synthelabo Recherche (Toulouse, France). Both compounds were solubilized in pure DMSO for the in vitro assays and in 5% DMSO and 5% Cremophor EL in saline when administered to mouse, rat, and gerbil. Rat/human CRF, ovine CRF, [D-Phe 11 ,His 12 ]Svg (antisauvagine-30), and rat/human CRF (6 -33) SSR125543A, a New Nonpeptide CRF 1 Receptor Antagonist gen (Cergy Pontoise, France). All other chemicals were from commercial sources.
Cell Cultures
CHO cells stably transfected with the human CRF 1 receptor (hCRF 1 -CHO cells) or with the human CRF 2␣ receptor (hCRF 2␣ -CHO cells) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat inactivated fetal calf serum, 300 g/ml Lglutamine, nonessential amino acids, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.17 g/ml amphothericine. Y 79 cells purchased from American Type Culture Collection (Rockville, MD) were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum and 300 g/ml L-glutamine.
AtT-20 cells purchased from American Type Culture Collection were cultured in Dulbecco's modified Eagle's medium containing only in supplement 10% fetal calf serum, 300 g/ml L-glutamine, HEPES, and sodium pyruvate. Cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 except AtT-20, which was incubated with 15% CO 2 .
Preparation of Cell Membrane Homogenates
Cells were cultured to confluence and the flasks were washed with 10 ml of phosphate-buffered saline (PBS) medium and filled with an equal volume of PBS medium. Cells (hCRF 1 -CHO, hCRF 2␣ -CHO, and AtT-20) were detached from the flask with a cell scraper. Y 79 cells were cultured in suspension. After centrifugation at 800g for 5 min, the cell pellet was homogenized at 4°C by using a Polytron (setting 6, 2 ϫ 20 s) in 50 mM Tris-HCl pH 7.4, 2 mM EDTA buffer for hCRF 1 -CHO and hCRF 2␣ -CHO cells. Homogenization was performed in 50 mM Tris-HCl pH 7.2, 10 mM MgCl 2 , 2 mM EDTA, 0.1% serum bovine albumin, 8 mg/l aprotinin, and 0.5 mg/ml soybean trypsin inhibitor for Y 79 cells. After centrifugation at 40,000g for 20 min at 4°C, the pellet was homogenized at 4°C by using a Polytron in binding buffer (see below). Aliquots obtained from the membrane suspension were stored in liquid nitrogen.
Preparation of Brain Membrane Homogenates
Because the in vivo pharmacological profile of the compound was to be characterized in rodents, the inhibitory effects of SSR125543A on [ 125 I-Tyr 0 ] ovine CRF binding to rat, mouse, and gerbil brain were assessed.
Mouse, rat, and gerbil were sacrificed by decapitation and brains were rapidly removed and homogenized at 4°C by using a Polytron (setting 4, 30 s) in 50 mM Tris-HCl pH 7.4, 2 mM EDTA buffer. After centrifugation at 40,000g for 20 min at 4°C, the 0.5-mg/ml pellet was homogenized at 4°C by using a Polytron in binding buffer (see below). Aliquots obtained from the membrane suspension were stored were stored at Ϫ80°C.
CRF 1 Receptor Binding Assay
[ 125 I-Tyr 0 ] ovine CRF binding was performed with hCRF 1 -CHO cell membranes, Y 79 cell membranes, or rodent brain membrane homogenates in the presence of 25 pM radiolabeled CRF in 50 mM Tris-HCl pH 7.2, 10 mM MgCl 2 , 2 mM EDTA, 0.1% serum bovine albumin, 8 mg/l aprotinin, and 0.5 mg/ml soybean trypsin inhibitor under a final volume of 400 l. Nonspecific binding was determined in the presence of 1 M rat/human CRF. Agonists and antagonists were added in 1% DMSO (final concentration). After incubation at 20°C for 2 h, the incubation mixture was filtered on Whatman GF/B filters presoaked in 0.5% bovine serum albumin solution for 2 h. The filters were washed twice with ice-cold Tris-HCl pH 7.2 buffer and the radioactivity was determined with a gamma scintillation counter (LKB 1261 multi gamma; EG G Instruments, Evry, France). Specific binding was determined as the difference between total and nonspecific binding. IC 50 values were determined using a nonlinear leastsquare regression analysis (Munson and Rodbard, 1980) with RS/1 (BBN Software Product Corporation, Cambridge, MA) and an internal computerized interactive procedure.
CRF 2 Receptor Binding Assay
[ 125 I-Tyr 0 ] sauvagine binding was performed using a similar protocol as with [ 125 I-Tyr 0 ] ovine CRF binding. In this case, hCRF 2␣ -CHO cell membranes were used at the concentration of 2.5 g of protein/tube in presence of 20 pM radiolabeled sauvagine, under a final volume of 250 l. Nonspecific binding was determined in presence of 1 M unlabeled sauvagine.
CRF-BP Binding Assay
Displacement of CRF from CRF-BP was measured by a detergent phase separation assay. Recombinant human CRF-BP was incubated at 20°C for 2 h with 30 pM [ 125 I-Tyr 0 ] rat/human CRF in 0.02% Nonidet-40 phosphate-buffered saline, pH 7.4. Bound and free CRF were then separated by the addition of Triton X-114 (octylphenoxypolyethoxyethanol) buffer stirring and incubation 20 min at 37°C. Free CRF segregates to the detergent phase at the bottom of the tube, and the CRF/CRF-BP complex remains in the aqueous phase. The amount of radioactivity in an aliquot of the aqueous phase was determined with a gamma scintillation counter (LKB 1261 multi gamma; EG G Instruments). Values were expressed as the mean Ϯ S.E.M. of at least three determinations performed in triplicate. Specific binding was determined as in CRF 1 binding assays.
Measurement of Intracellular cAMP Synthesis in Y 79 Cells
CRF-induced cAMP synthesis in human retinoblastoma Y 79 cells was assessed as described by Hauger et al. (1997) . In the present article, two types of experiments were performed on Y 79 cells. In the first experiment, Y 79 cells were incubated for 15 min at 37°C under stirring in presence of 10 nM rat/human CRF with increasing concentrations of SSR125543A in 1 mM isobutylmethyl xanthine supplemented RPMI buffer, pH 7.2. The intracellular cAMP content was measured after lysing the cells by 0.5% ice-cold Triton X-100 by using a cAMP 125 I scintillation proximity assay kit (Amersham Biosciences plc, Little Chalfont, Buckinghamshire, UK). IC 50 values were determined using a nonlinear least-square regression analysis (Munson and Rodbard, 1980) with RS/1 (BBN Software Product Corporation) and an internal computerized interactive procedure.
In the second experiment, Y 79 cells were incubated for 15 min at 37°C under stirring with increasing concentrations of rat/human CRF alone or in presence of three concentrations of SSR125543A. Intracellular cAMP synthesis was expressed as the percentage of maximal release after subtraction of basal release. Values were expressed as the mean of at least three determinations performed in duplicate.
Measurement of ACTH Secretion by AtT-20 Cells
CRF-induced ACTH secretion in mouse pituitary AtT-20 cells was previously described by Litvin et al. (1984) . A subclone of AtT-20/ D16v cells was used in this study. Cells were seeded in 12-well plates and cultured overnight in their growth medium. They were incubated for 120 min at 37°C with 2 ml of basal medium, alone or with increasing concentrations of rat/human CRF in the presence or absence of three concentrations of SSR125543A. ACTH release was measured on supernatant samples by using a radioimmunoassay (Diasorin, Stillwater, MN). Values were expressed as mean values of three determinations performed in triplicate.
Ex Vivo Binding Assay in Rats
SSR125543A or the corresponding vehicle was administered p.o. or i.v. to rats (three per group) at various doses (dose-effect studies) and times (time course studies) before rat decapitation and organ (brain and pituitary) removal. Tissues were homogenized in 10 ml of incubation buffer by using a Polytron (speed 21,500 rpm ϫ 17 s) then 324 Gully et al.
diluted (1/20) with the same incubation buffer and submitted to a [ 125 I-Tyr 0 ] ovine CRF binding assay procedure as previously described. To determine the relative population of CRF 1 binding sites present in crude homogenates from rat brain and pituitary, binding studies were performed in vitro, on naïve brain and pituitary tissue. Competition curves were determined for ovine CRF, antisauvagine-30, and rat/human CRF (6 -33) , two peptides selective for CRF 2 receptor and CRF-BP, respectively (Behan et al., 1995; Ruhmann et al., 1998) . In the ex vivo binding assay, nonspecific binding was defined with 100 nM antalarmin. Values were expressed as the mean percentage of specific binding Ϯ S.E.M. Statistical differences between drug-and vehicle-treated groups were assessed by a Student's t test.
CRF-Induced ACTH Secretion in Rats
Animals were habituated to the experimental procedure 1 day before the experiment. SSR125543A or its vehicle was administered p.o. or i.v. to rats (3-7/group) at various doses (dose-effect studies) and times (time course studies) before intravenous injection of 4 g/kg rat/human CRF. Thirty minutes later, animals were sacrificed by decapitation and trunk blood samples were collected in a 1 mg/ml EDTA solution for the determination of ACTH plasma levels by radioimmunoassay (Diasorin). Results were expressed as the mean values Ϯ S.E.M. Statistical differences between drug-and vehicletreated groups were assessed by a Student's t test. The median inhibitory doses (ID 50 ) with 95% confidence limits were determined by fitting of the dose-response curve to the four-parameter logistic model according to Ratkowsky and Reedy (1986) . The adjustment was performed by nonlinear regression by using the Levenberg-Marquardt algorithm in the RS/1 software.
Restraint Stress-Induced ACTH Secretion in Rats
One hour after oral administration of SSR125543A or its vehicle, rats were placed into hemicylindrical Plexiglas enclosures (6 cm in width and 4 cm in height) for 15 min. After this stress period, the animals were placed back in their cages, carried to an adjacent room and immediately sacrificed. Nonstressed control animals remained in their cage for 15 min before sacrifice. Blood was collected in a 1 mg/ml EDTA solution for the determination of ACTH plasma levels by radioimmunoassay (Diasorin). Values were expressed as the mean ACTH levels Ϯ S.E.M. Statistical differences between drugand vehicle-treated groups were assessed by a single factor ANOVA or by the nonparametric Kruskall-Wallis test followed by Dunnett's t test or by the Mann-Whitney U test with ␣ adjustment of Holm on RS1/software, respectively.
CRF-Induced Hippocampal Acetylcholine Release
Surgery and Microdialysis. Rats were anesthetized with urethane (1.4 g/kg i.p.) and then placed in a stereotaxic frame. A microdialysis probe (CMA-12, length 2 or 3 mm and outer diameter 0.5 mm; Carnegie Medicine AB, Stockholm, Sweden) was stereotaxically implanted in the dorsal hippocampus. The coordinates were 3.5 mm posterior to bregma, 2 mm lateral to the midline, and 3.8 mm down from the dural surface for the hippocampus (Paxinos and Watson, 1986) . For i.c.v. injection of CRF, ejection pipettes were implanted into the left lateral ventricle at the following coordinates: 0.8 mm posterior to bregma, 1.5 mm lateral to the midline, and 3.4 mm down from the dural surface. The ejection of CRF (1 g/2 l/90 s) was performed by applying air pressure with a 1-ml syringe connected to the nontapered side of the pipette by Tygon tubing. The probes were perfused with a gassed Ringer's solution containing 125 mM NaCl, 3 mM KCl, 1.3 mM CaCl 2 , 1.0 mM MgCl 2 , 23 mM NaHCO 3 , and 1.5 mM KH 2 PO 4 , pH 7.4, at a rate of 2 l/min by using a microinjection pump (CMA-100; Carnegie Medicine AB). To reduce acetylcholine degradation in the dialysate, 1 M neostigmine was added to the Ringer's solution perfused in the hippocampal probe. Microdialysis sampling started 90 min after the probe was placed in the hippocampus. Serial samples were collected at 30-min intervals. SSR125543A, antalarmin, and vehicle were given intraperitoneally (5 ml/kg of body weight) 180 and 30 min before peptide application.
The time course of the CRF effects was analyzed by ANOVA with repeated measures and Dunnett's t test was used for individual time comparisons. The antagonism of the CRF effect was evaluated by comparing the area under the curve during the 120 min after peptide injection. A statistical analysis was carried out by using the Student's t test.
Assay of Acetylcholine (ACh). ACh levels were measured in 30-min dialysate samples (50 l) by using a high-performance liquid chromatography system (Waters, Milford, MA) as previously described by Steinberg et al. (1995) except for the electrochemical detection system (Coulochem II; ESA, Chelmsford, MA). Briefly, the analytical system for ACh included a trapping precolumn and immobilized enzyme reactor (BAS.MF-6151). The mobile phase, 35 mM phosphate buffer, pH 8.5, supplemented with the antibacterial reagent Kathon (5 ml/l; BAS DF-2150), was pumped at a flow rate of 0.8 ml/min and replaced with a fresh preparation every 3 days. The enzyme postcolumn reactor converted ACh to hydrogen peroxide that was electrochemically detected using a platinum electrode (ESA P/N 55-0183) set at 0.3 V. The chromatographic column and enzyme reactor were kept at 35°C. The detection sensitivity was 0.2 pmol/50 l.
CRF-Induced Forepaw Treading in Gerbils
This test was based on the observation that i.c.v. injection of CRF (1 g/2 l) produces forepaw treading ("piano playing") in gerbils, an effect that is prevented by treatment with the CRF 1 receptor antagonist R-121919 (Owens and Nemeroff, 1999) . Gerbils were placed individually in small transparent plastic cages for 30 min. They were then pretreated with SSR125543A p.o. or antalarmin i.p. CRF (1 g) was injected i.c.v. (free-hand method; Jung et al., 1996) 15 min (antalarmin) or 60 min (SSR125543A) later. In each experiment, a control group was injected i.c.v. with the vehicle. Forepaw treading was measured by an observer unaware of the drug treatment, for 1 min every 15 min over a 2-h period (8 min in total cumulative times). The cumulative forepaw treading time was calculated for each gerbil and then expressed as the mean and S.E.M. Comparisons between control and treated groups were performed using the Kruskall-Wallis test, followed by Mann-Whitney U test with ␣ adjustment of Holm.
Results

Affinity of SSR125543A for CRF 1 Receptors
SSR125543A inhibited the specific binding of [ 125 I-Tyr 0 ] ovine CRF to human CRF 1 receptors expressed in CHO cells with a pK i value of 8.73 Ϯ 0.15 (mean Ϯ S.E.M.; Table 1) , which was comparable to that of antalarmin and higher than that of the natural ligand rat/human CRF (pK i ϭ 8. 70 and 8.22, respectively) . It also recognized with high affinity the native CRF 1 receptors present on the human retinoblastoma cell line Y 79 (pK i ϭ 9.08 Ϯ 0.20). At 10 M, SSR125543A did not interact with the human CRF 2␣ receptor expressed in CHO cells, or human and rat recombinant CRF-BP (Table 1) .
Binding studies performed with [ 125 I-Tyr 0 ] ovine CRF on membrane preparations obtained from rodent brains (rat, mouse, and gerbil) did not reveal species differences in affinity because the respective pK i values of 8.77 Ϯ 0.23, 8.90 Ϯ 0.10, and 9.00 Ϯ 0.00 were very close to the pK i for the human CRF 1 receptor ( Table 1 ). The high selectivity of SSR125543A for the CRF 1 receptor was demonstrated by its lack of activity (inhibition lower than 50%) at 1 or 10 M in 125 assays performed by Panlabs and Cerep (receptors, transporters, enzymes, and ion channels) ( Table 2) .
CRF 1 Receptor Antagonism by SSR125543A: In Vitro Studies
When rat/human CRF was applied to Y 79 cells, which express constitutively CRF 1 receptors, the intracellular cAMP production was increased by ϳ7-fold over basal levels, with an EC 50 value of 4.0 Ϯ 0.9 nM (mean Ϯ S.E.M). SSR125543A did not modify the basal level of cAMP but fully blocked the CRF (10 nM) response with an IC 50 value of 3.0 Ϯ 0.4 nM (mean Ϯ S.E.M., n ϭ 3; Fig. 2A ). Under similar experimental conditions, the IC 50 for antalarmin was 0.8 Ϯ 0.1 nM (mean Ϯ S.E.M., n ϭ 3; data not shown). Increasing concentrations of SSR125543A produced a rightward shift of the rat/human CRF concentration-response curve (Fig. 2B) , without modifying the maximal cAMP production obtained with rat/human CRF alone. EC 50 values for CRF were 2.5 nM (2.1-2.9), 8.3 (5.5-12.4), 55.6 (42.5-73.0), and 92.2 (55.7-144.9) (means and confidence limits) in the presence or absence of 3, 30, and 100 nM SSR125543A, respectively.
When rat/human CRF was applied to mouse pituitary AtT-20 cells, which express CRF 1 receptors, ACTH secretion was stimulated by ϳ3-fold over basal levels. SSR125543A did not modify basal secretion of ACTH but antagonized the ACTH secretion induced by increasing concentrations of rat/ human CRF. Increasing concentrations of SSR125543A also produced a rightward shift of the rat/human CRF dose-response curve and a concentration-dependent inhibition of the maximal ACTH secretion elicited by rat/human CRF alone (Fig. 3) . In the course of three experiments, EC 50 values for CRF were 1.6 (1.4 -1.9), 11.9 (10.0 -14.1), 49.8 (34.2-74.3), and 128.1 (104.6 -160.0) (means and confidence limits) in the presence or absence of 3, 30, and 100 nM SSR125543A, respectively.
Ex Vivo Binding Assay
The nonspecific binding obtained in the presence of 1 M rat/human CRF in the ex vivo [ 125 I-Tyr 0 ] ovine CRF binding assay averaged 20%. To determine the real proportion of CRF 1 binding sites in this model, competition studies were performed with ovine CRF, antalarmin, SSR125543A, antisauvagine-30, and rat/human CFR (6 -33) on crude brain and pituitary homogenates prepared from untreated rats. As shown in Fig. 4A and Table 3 , the binding of radiolabeled ovine CRF could be competed by ovine CRF with a biphasic curve, suggesting two populations of 50 and 30% of the total binding sites and respective pK i values of 8.35 and 6.23. Antalarmin and SSR125543A displaced only the first population of sites in a monophasic manner and similar pK i values of 8.80 and 8.89. Antisauvagine-30 competed weakly with iodinated ovine CRF with a shallow monophasic curve (pK i ϭ 6.77, n H ϭ 0.67). In contrast, the selective CRF-BP ligand rat/human CRF (6 -33) inhibited only 30% of the total binding that represents the non-CRF 1 component. Its low affinity for ovine CRF compared with rat/human CRF explains the weak pK i (6.43) measured in this study. Unlike crude brain membranes, the specific binding of [ 125 I-Tyr 0 ] ovine CRF to crude rat pituitary homogenates represented 90% of the total binding and was completely displaced by 100 nM antalarmin. Taking into account the high selectivity of antalarmin, CRF 1 specific binding to crude tissue homogenates was considered as the maximal displacement measured in the presence of 100 nM antalarmin.
The blockade of brain and pituitary CRF 1 receptors was evaluated in binding studies performed on crude tissue homogenates prepared from rats treated with SSR125543A (ex vivo binding assay). No specific CRF 1 binding could be measured after a 2-h oral treatment at the dose of 30 mg/kg, whereas at 4 h postadministration, the binding was still reduced by 76 Ϯ 2% (Fig. 4C) . The presence of SSR125543A at the pituitary level was also demonstrated in the same experiment, by a decrease of 67 Ϯ 1% in binding 1 h after SSR125543A oral administration that reached 78 Ϯ 1% at 2 and 4 h (Fig. 4C) . Another experiment performed under similar conditions demonstrated that ligand binding inhibition was still present 24 h after SSR125543A treatment, with 62 Ϯ 14% inhibition in the brain and 80 Ϯ 2% in the pituitary (mean and S.E.M., n ϭ 3). Dose-effect study performed 2 h after oral treatment revealed a dose-dependent inhibition of brain CRF 1 receptor binding with an ID 50 of 6.5 (3.2-11.8) mg/kg (mean and confidence limits; Fig. 4B ). SSR125543A also reached both brain and pituitary after i.p. injection, ID 50 determined 2 h post-treatment being 11.7 (6.0 -23.0) mg/kg, slightly higher than after oral administration (data not shown).
CRF 1 Receptor Antagonism by SSR125543A: In Vivo Studies
CRF-Induced ACTH Secretion in Rats.
In conscious rats, the plasma level of ACTH determined by radioimmunoassay was 34 Ϯ 4 pg/ml (mean Ϯ S.E.M., n ϭ 12). Oral administration of 30 mg/kg SSR125543A, 2 h before blood sampling significantly diminished the ACTH level (18 Ϯ 2 pg/ml, p Ͻ 0.01, n ϭ 5). CRF (4 g/kg i.v.) injection, 30 min before blood sampling, induced a more than 10-fold stimulation (269 Ϯ 20 pg/ml) of the ACTH secretion. When administered orally at the dose of 30 mg/kg, SSR125543A inhibited the increase in ACTH secretion induced by CRF injection with significant effects from 1 to 6 h (Fig. 5A) . Dose-effect studies performed after oral administration of SSR125543A, 2 h before the CRF injection, yielded ID 50 values of 4.9 (3.0 -8.6) mg/kg (Fig. 5B ) (means and confident limits). After i.v. injection of 3 mg/kg SSR125543A, the maximal inhibition of CRF-induced ACTH secretion was observed at 5 min postinjection. The dose-effect study performed at the same time yielded an ID 50 of 1.3 (1.2-1.4) mg/kg i.v. (Fig. 5C ). Guinea pig brain (1) and striatum (2) ; Rat brain ( Human U937 cells (1) ; Guinea pig lung (2) Melanocortin MC 4
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SSR125543A, a New Nonpeptide CRF 1 Receptor Antagonist
Stress-Induced ACTH Secretion in Rats.
A 15-min restraint stress caused a marked elevation of ACTH plasma levels (4-or 6-fold stimulation) in rats. This increase was significantly antagonized by oral administration of 10 (but not 3) mg/kg SSR125543A (given 1 h before the stress session) (p Ͻ 0.01, n ϭ 9) (Fig. 6 ). Under similar experimental conditions, 30 mg/kg antalarmin also produced a significant decrease of the CRF response, which was lesser in extent than that of SSR125543A (p Ͻ 0.05, n ϭ 10).
CRF-Induced Hippocampal ACh Release in Rats. In anesthetized rats, the i.c.v. injection of 1 g/2 l CRF produced a rapid increase in extracellular ACh levels measured in dialysates from the hippocampus (Fig. 7A) . In both groups, a significant increase was observed at 60 min (p Ͻ 0.01) after CRF injection, which persisted up to 120 min postinjection with a maximal effect at 90 min (ϩ135 Ϯ 28 and ϩ 84 Ϯ 14%, p Ͻ 0.01, n ϭ 9 and 8, respectively). SSR125543A (20 mg/kg) injected i.p. 3 h before the administration of CRF (p Ͻ 0.05, n ϭ 7) partially antagonized the CRF-evoked hippocampal ACh release as measured by the area under the curve during the 120-min sampling period after CRF injection (Fig. 7B) . Similarly, 30 mg/kg antalarmin injected i.p. 30 min before CRF significantly (p Ͻ 0.01, n ϭ 6) reduced the peptide response.
CRF-Induced Forepaw Treading in Gerbils. The results presented in Table 1 show that forepaw treading produced by i.c.v. injection of CRF was significantly attenuated by pretreatment with SSR125543A ( 2 ϭ 29.32, p Ͻ 0.01) and antalarmin ( 2 ϭ 27.66, p Ͻ 0.01) at the doses of 10 and 30 mg/kg, respectively, 60 and 15 min before CRF injection (Table 4 ).
Discussion
This study describes the biochemical and pharmacological properties of SSR125543A, a novel nonpeptide antagonist of CRF 1 receptors. SSR125543A inhibits the specific binding of [ 125 I-Tyr 0 ] ovine CRF to the CRF 1 receptor cloned from human brain and stably expressed in CHO cells (hCRF 1 -CHO), with a nanomolar affinity close to that of the natural ligand rat/human CRF and of antalarmin, another nonpeptide CRF 1 receptor antagonist. The high affinity of SSR125543A for the native human CRF 1 receptor was demonstrated in membrane preparations obtained from cultured human retinoblastoma Y 79 cells that constitutively express CRF 1 receptors. SSR125543A recognized with the same affinity CRF 1 receptors from rat, mouse, and gerbil brain, demonstrating no species difference between human and rodent. This compound is 1000-fold more selective for human CRF 1 than for human CRF 2␣ receptors or human CRF binding protein. The selectivity of SSR125543A for the CRF 1 receptor was also demonstrated by its lack of activity, when tested at high concentrations (1 or 10 M, in a panel of binding assays for neurotransmitters and their transporters, peptides and hormones, or enzymes and ion channels.
The binding of CRF to CRF 1 receptors has been reported to increase adenylate cyclase activity and in turn cAMP levels in cells transfected with the CRF 1 receptor and to stimulate ACTH secretion from pituitary corticotrophs. The present study clearly demonstrates that SSR125543A behaves as a nanomolar CRF 1 receptor antagonist, devoid of agonist properties. It concentration dependently inhibited CRF-induced cAMP production in the human retinoblastoma Y 79 cell line in a competitive manner. The compound also inhibited ACTH secretion induced by CRF in the pituitary tumor AtT-20 cell line. However, the observed rightward shift was associated with a concentration-dependent diminution of secretion level, which suggested a noncompetitive inhibition in these murine cells.
The ability of SSR125543A to reach the pituitary and the brain has been demonstrated in ex vivo binding assays performed in rats after both oral and i.p. administration.
First, the relative population of CRF 1 binding sites present in crude homogenates was determined in [ 125 I-Tyr 0 ] ovine CRF binding studies performed in vitro, on naïve brain and pituitary tissues. Competition by ovine CRF revealed two populations of sites (representing 50 and 30% of total binding). Only 50% of sites displaced by the two selective CRF 1 receptor antagonists antalarmin and SSR125543A were relevant to CRF 1 receptors. The antisauvagine-30 weakly competed with the ligand (pK i ϭ 6.77) and did not discriminate between these two populations. Its low affinity suggests that the non-CRF 1 component recognized by this peptide does not correspond to CRF 2 binding sites. Rat/human CRF (6 -33) concentration dependently inhibited only the second (30%) population of binding sites. The measured pK i ϭ 6.44 is in agreement with the lower affinity of this competitor for ovine CRF used as radioligand in our study. The non-CRF 1 component, not displaced by antalarmin and SSR125543A, may correspond to the CRF-BP present in rat brain crude homogenate. It is worth noting that in similar experimental conditions, CRF 1 binding (90% of the total binding) to rat pituitary homogenates was totally displaced by 100 nM antalarmin and corresponded to the specific binding. Taking into account the CRF 1 receptor selectivity of antalarmin, 100 nM this compound was used to define CRF 1 specific binding in subsequent studies.
In ex vivo binding experiments, SSR125543A dose dependently prevented the binding of radiolabeled CRF to CRF 1 binding sites in tissue homogenates, suggesting its presence in the pituitary and in the brain, respectively, at 1 and 2 h after oral administration. Moreover, the inhibitory effects of Growing evidence implicates elevated HPA function and CRF-mediated neurotransmission in human anxiety and depression. Because of its selective stimulation of the corticotrope cells of the pituitary gland, CRF can lead to exacerbated ACTH secretion. In humans, CRF injection elevates both plasma ACTH and cortisol levels, increases the respiratory drive, and results in hypotension and flushing. Currently, the clinical uses of CRF ("CRF challenge") are limited to the diagnosis of HPA dysfunctions (Chrousos et al., 1984) . Because the pituitary is located outside the blood-brain barrier, the HPA axis is better activated by systemic rather than by central administration of CRF.
In a similar animal model the effect of SSR125543A on ACTH secretion induced by i.v. injection of CRF was studied under nonstressful conditions in freely moving rats. Treatment with SSR125543A 2 h before CRF injection dose dependently prevented the stimulating effect of CRF on ACTH secretion, regardless of the route of administration (p.o. or i.v.). Furthermore, these results demonstrated that the compound is orally active and are in accordance with the presence of the compound within the pituitary as revealed by the ex vivo binding assays.
The hormonal response to stress is triggered by in- creased CRF secretion from the paraventricular neurons of the hypothalamus into the hypothalamic-pituitary-portal system, leading to enhanced ACTH secretion by pituitary corticotropes and subsequent corticosteroid secretion by the adrenal gland (cortisol in primates and corticosterone in rats) (Owens and Nemeroff, 1991) . The above-mentioned changes in hormone secretion are commonly observed in animals under stress conditions. Indeed, ACTH release appears to be a constant feature of the response to most types of stressors (Gibbs, 1984) and changes in pituitaryadrenal tone reflect the intensity of stimulation to which an organism is exposed (Hennessy and Levine, 1978) . Restraint and immobilization stress in rats, which requires the animal's cognitive appraisal of the situation, is often considered as a model of psychological stimuli that in turn stimulate the HPA axis (De Souza and Van Loon, 1985) . Consequently, a 15-min restraint period has been used to evaluate the ability of SSR125543A to antagonize HPA axis hyperactivity. This stress procedure induces a 10-fold elevation of plasma ACTH levels 13 min after the initiation of stress. Stress-induced ACTH release was antagonized by oral administration of the two CRF 1 receptor antagonists SSR125543A (10 mg/kg) and antalarmin (30 mg/kg), 1 h before the stress session. These results confirm that SSR125543A is able to antagonize the hormonal stimulating effect of endogenously produced CRF in a situation that reproduces the clinical condition seen in patients suffering from affective disorders.
In addition to the hormonal role played by CRF in the activation of the HPA axis, this peptide also behaves as a neurotransmitter and/or neuromodulator in the central nervous system and promotes various physiological and behavioral changes (Dunn and Berridge, 1990; Menzaghi et al., 1993) . Moreover, neurochemical studies have demonstrated that acute experimental stress in rats increases the synthesis and release of brain noradrenaline, dopamine, and 5-hydroxytryptamine. Centrally acting CRF increases arousal as defined behaviorally (Sutton et al., 1982) and electroencephalographically (Ehlers et al., 1983) . Based on the effects of CRF on cognitive tasks and the fact that pathological stress can be considered as a "toxic" effect of excessive arousal (Hennessy and Levine, 1979) , CRF has been proposed to be a positive regulator of cholinergic tone in the CNS. In support of this view, i.c.v. CRF injection has been demonstrated to increase ACh release in the rat hippocampus (Day et al., 1998) . Microdialysis experiments showed that i.p. injection of 10 mg/kg SSR125543A, 3 h before i.c.v. CRF challenge, antagonized ACh release evoked by CRF in the rat hippocampus. Similar results were obtained with 30 mg/kg antalarmin administered i.p., 30 min before the peptide.
In addition to an increase in arousal, i.c.v. CRF injection elicits a number of behavioral responses that depend on the testing conditions. For example, the threshold dose of CRF to induce grooming may be related to stress, because rats exposed to a novel environment display increased grooming behavior that habituates with repeated exposure to the same environment (Colbern et al., 1978) . When i.c.v. injected in several animal species, CRF elicits a high frequency tremor of the forelimbs called forepaw treading or piano-playing. This behavior is specifically linked to CRF 1 receptor stimulation because it is not seen after i.c.v. urotensin injection (Britton et al., 1984) . In gerbils, CRF induces a smaller effect on grooming behavior than in rats, which allows the observation of forepaw treading. Oral administration of SSR125543A and antalarmin before CRF injection was found to significantly and dose dependently (10 -30 mg/kg) reduce piano-playing behavior in gerbils.
In summary, SSR125543A is a potent and selective CRF 1 receptor antagonist coming from a new chemical family. It is orally active, has a long duration of action, and readily Fig. 7 . Effects of SSR125543A and antalarmin on acetylcholine release evoked in rat hippocampus by i.c.v. injection of 1 g of CRF. A, effect of CRF (1 g i.c.v.) on hippocampal ACh release. The changes in ACh levels are expressed as the percentage of the mean value of the four basal samples before CRF application. Each data point represents the mean value Ϯ S.E.M of eight to nine animals. ૺ, p Ͻ 0.05, ૺૺ, p Ͻ 0.01 compared with vehicle control group by ANOVA with repeated measures and the Dunnett's t test. B, reversal of CRF-induced ACh release by SSR125543A and antalarmin injected i.p., 180 and 30 min, respectively, before CRF injection. The data are the mean area under the curve Ϯ S.E.M of five to nine animals for the 120 min after CRF injection. ૺ, p Ͻ 0.05; ૺૺ, p Ͻ 0.01; and †, p Ͻ 0.05 compared with CRF respective control group by ANOVA followed by Student's t test or Dunnett's t test. 
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crosses the blood-brain barrier. SSR125543A will be a useful tool for better understanding the role of CRF in anxiety, depression, and cognitive function. As shown in the accompanying article (Griebel et al., 2002) , SSR125543A reduces anxiety and depressive-related responses in several animal models, and as such, has a potential in the treatment of depression and some forms of anxiety.
